New hope for advanced lung cancer: heat therapy plus drugs tested after first treatment fails
NCT ID NCT07528274
First seen Apr 18, 2026 · Last updated Jun 12, 2026 · Updated 12 times
Summary
This study tests a new approach for people with advanced non-small cell lung cancer whose disease has worsened after initial immunotherapy and chemotherapy. Participants will receive a combination of microwave ablation (using heat to destroy tumors), the immunotherapy drug tislelizumab, and the chemotherapy drug docetaxel. The goal is to see if this combination can delay cancer progression. About 20 adults will take part in this phase 2 trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC (NON-SMALL CELL LUNG CANCER) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin Cancer Hospital Airport Hospital
RECRUITINGTianjin, Tianjin Municipality, 300308, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.